Q4 2024 Rxsight Inc Earnings Call Transcript
Key Points
- RxSight Inc (RXST) reported a 41% increase in revenue for Q4 2024 compared to the same quarter in the previous year, driven by strong growth in LAL procedure volume.
- The company achieved a record sale of 2,969 LALs in Q4 2024, marking a 61% increase from Q4 2023.
- Gross margin expanded to 71.6% in Q4 2024, up from 61.8% in Q4 2023, due to a favorable revenue mix and lower manufacturing costs.
- RxSight Inc (RXST) ended 2024 with no debt and $237.2 million in cash equivalents and short-term investments.
- The company received FDA approval for additional LDD functionality, enhancing customization options for cataract surgery, which is expected to be released in the second half of 2025.
- RxSight Inc (RXST) reported a net loss of $5.9 million in Q4 2024, although this was an improvement from the $9.2 million loss in Q4 2023.
- SG&A expenses increased by 33% year-over-year in Q4 2024, primarily due to higher sales and clinical personnel costs.
- Research and development expenses rose by 25% year-over-year in Q4 2024, driven by increased facility costs and stock-based compensation.
- Revenue contribution from outside North America is expected to remain nominal in 2025, with more meaningful impact anticipated in 2026 and beyond.
- The company anticipates operating expenses to increase by 22% to 25% in 2025, reflecting ongoing investments in sales, marketing, and R&D.
Ladies and gentlemen, thank you for standing by. My name is Desiree and I will be your conference operator today. At this time, I would like to welcome everyone to our site 4th quarter 2024 earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star, followed by the number one on your telephone keypad.
If you would like to withdraw your question again, press the star one. I would now like to turn the conference over to Oliver Mavchevich, Vice President, Investor relations. You may begin.
Thank you, operator. Presenting today are RXI President and Chief Executive Officer, Doctor Ron Kurtz and Chief Financial Officer Shelley Tunan. Earlier today, RXI released financial results for the three months ended December 31, 2024. A copy of the press release is available on the company's website.
Before we begin, I would
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
